Physician profile
Bindu Akkanti
NPI 1982663514
$184,861.55
in general payments reported to CMS, 2019-2025
22 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $250 · 2021: $11K · 2022: $13K · 2023: $43K · 2024: $65K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Honoraria: $52K · Consulting Fee: $33K · Travel and Lodging: $15K · Food and Beverage: $5,010 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,380.00 |
| Honoraria | $52,250.00 |
| Consulting Fee | $32,725.00 |
| Travel and Lodging | $15,110.59 |
| Food and Beverage | $5,010.42 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $90,011.08 | 2022-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $80,073.20 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $8,237.94 | 2021-2025 | Tyvaso, Tyvaso |
| Livanova USA, INC. | $4,123.73 | 2023 | Hemolung Cartridge Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.45 | 2019-2025 | Ofev, Jascayd |
| Abbott Laboratories | $483.62 | 2022-2025 | Aveir, Agilis Hispro, Cardiomems |
| Allergan, INC. | $268.95 | 2019-2020 | |
| Boston Scientific Corporation | $193.94 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.36 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $137.72 | 2023-2025 | |
| Inari Medical, INC. | $131.78 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals Lp | $117.72 | 2024 | |
| Fresenius USA Marketing, INC. | $83.22 | 2025 | Novalung System |
| Insmed, INC. | $69.47 | 2024-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $34.72 | 2025 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $30.20 | 2019-2023 | Treprostinil |
| Glaxosmithkline, LLC. | $25.82 | 2024 | Nucala |
| Gilead Sciences, INC. | $22.93 | 2019 | |
| Novo Nordisk INC | $21.21 | 2024 | Ozempic |
| Masimo Corporation | $18.49 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Akkanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.